TUFM
Basic information
Region (hg38): 16:28842411-28846348
Links
Phenotypes
GenCC
Source:
- combined oxidative phosphorylation defect type 4 (Strong), mode of inheritance: AR
- combined oxidative phosphorylation defect type 4 (Supportive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Combined oxidative phosphorylation deficiency 4 | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Biochemical; Gastrointestinal; Neurologic | 17160893 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the TUFM gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 31 | 34 | ||||
missense | 66 | 70 | ||||
nonsense | 1 | |||||
start loss | 1 | |||||
frameshift | 1 | |||||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 3 | 7 | 10 | |||
non coding | 18 | 27 | 54 | |||
Total | 0 | 3 | 90 | 59 | 10 |
Variants in TUFM
This is a list of pathogenic ClinVar variants found in the TUFM region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
16-28842414-T-A | Combined oxidative phosphorylation defect type 4 | Conflicting classifications of pathogenicity (Jun 01, 2023) | ||
16-28842458-C-G | Combined oxidative phosphorylation defect type 4 | Uncertain significance (Jan 12, 2018) | ||
16-28842530-C-T | Combined oxidative phosphorylation defect type 4 | Uncertain significance (Jan 12, 2018) | ||
16-28842542-A-G | Combined oxidative phosphorylation defect type 4 | Uncertain significance (Jan 13, 2018) | ||
16-28842577-C-T | Combined oxidative phosphorylation defect type 4 | Uncertain significance (Jan 12, 2018) | ||
16-28842605-A-C | Combined oxidative phosphorylation defect type 4 | Uncertain significance (Jan 13, 2018) | ||
16-28842626-C-T | Combined oxidative phosphorylation defect type 4 | Uncertain significance (Jan 13, 2018) | ||
16-28842675-A-C | Combined oxidative phosphorylation defect type 4 | Benign (Jun 14, 2018) | ||
16-28842705-G-A | Combined oxidative phosphorylation defect type 4 | Uncertain significance (Jan 13, 2018) | ||
16-28842746-C-T | Combined oxidative phosphorylation defect type 4 | Uncertain significance (Jan 13, 2018) | ||
16-28842826-C-G | Combined oxidative phosphorylation defect type 4 | Uncertain significance (Jan 12, 2018) | ||
16-28842865-T-C | Combined oxidative phosphorylation defect type 4 | Uncertain significance (Jan 12, 2018) | ||
16-28842915-A-C | Combined oxidative phosphorylation defect type 4 | Uncertain significance (Apr 27, 2017) | ||
16-28842938-C-T | Combined oxidative phosphorylation defect type 4 | Uncertain significance (Jan 12, 2018) | ||
16-28842951-G-A | Combined oxidative phosphorylation defect type 4 | Benign (Jul 15, 2018) | ||
16-28842979-C-T | Uncertain significance (Sep 03, 2024) | |||
16-28842985-T-A | Uncertain significance (Jan 02, 2022) | |||
16-28842990-ATTC-A | Uncertain significance (Jun 29, 2023) | |||
16-28842995-T-C | Combined oxidative phosphorylation defect type 4 • Inborn genetic diseases | Uncertain significance (Oct 24, 2022) | ||
16-28843006-G-T | Inborn genetic diseases | Uncertain significance (Dec 21, 2023) | ||
16-28843010-T-C | Uncertain significance (Sep 02, 2022) | |||
16-28843035-G-A | Likely benign (Jun 01, 2021) | |||
16-28843051-T-C | Combined oxidative phosphorylation defect type 4 • Inborn genetic diseases | Conflicting classifications of pathogenicity (Jan 22, 2024) | ||
16-28843059-T-G | Likely benign (Jan 15, 2024) | |||
16-28843072-C-T | Uncertain significance (Dec 02, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
TUFM | protein_coding | protein_coding | ENST00000313511 | 10 | 3998 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00418 | 0.989 | 125730 | 0 | 18 | 125748 | 0.0000716 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.40 | 205 | 269 | 0.761 | 0.0000174 | 2918 |
Missense in Polyphen | 62 | 108.29 | 0.57255 | 1122 | ||
Synonymous | 0.0910 | 114 | 115 | 0.989 | 0.00000743 | 982 |
Loss of Function | 2.37 | 7 | 17.8 | 0.393 | 0.00000101 | 220 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000289 | 0.0000289 |
Ashkenazi Jewish | 0.000198 | 0.000198 |
East Asian | 0.0000546 | 0.0000544 |
Finnish | 0.0000464 | 0.0000462 |
European (Non-Finnish) | 0.0000880 | 0.0000791 |
Middle Eastern | 0.0000546 | 0.0000544 |
South Asian | 0.0000980 | 0.0000980 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis. Plays also a role in the regulation of autophagy and innate immunity. Recruits ATG5-ATG12 and NLRX1 at mitochondria and serves as a checkpoint of the RIG-I/DDX58-MAVS pathway. In turn, inhibits RLR-mediated type I interferon while promoting autophagy. {ECO:0000269|PubMed:22749352, ECO:0000269|PubMed:28407488}.;
- Disease
- DISEASE: Combined oxidative phosphorylation deficiency 4 (COXPD4) [MIM:610678]: A mitochondrial disease resulting in neonatal lactic acidosis, rapidly progressive encephalopathy, severely decreased mitochondrial protein synthesis, and combined deficiency of mtDNA- related mitochondrial respiratory chain complexes. {ECO:0000269|PubMed:17160893}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Translation;Metabolism of proteins;Purine metabolism;Mitochondrial translation elongation;Mitochondrial translation
(Consensus)
Recessive Scores
- pRec
- 0.151
Intolerance Scores
- loftool
- 0.511
- rvis_EVS
- -0.4
- rvis_percentile_EVS
- 26.73
Haploinsufficiency Scores
- pHI
- 0.316
- hipred
- Y
- hipred_score
- 0.743
- ghis
- 0.572
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.923
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Tufm
- Phenotype
Gene ontology
- Biological process
- translational elongation;response to ethanol;mitochondrial translational elongation
- Cellular component
- mitochondrion;membrane;mitochondrial nucleoid;myelin sheath;synapse;extracellular exosome
- Molecular function
- RNA binding;translation elongation factor activity;GTPase activity;protein binding;GTP binding